Mohammad-Reza Ansari_Astaneh - Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Mehrdad Motamed Shariati - Eye research center, Mashhad University of Medical Sciences
Naser Shoeibi - Associate Professor, Eye Research Center, Department of Ophthalmology, Mashhad University of Medical Sciences, Mashhad, Iran
Seyedeh Maryam Hosseini - Eye Research Center, Mashhad university of Medical Sciences
Mojtababa Abrishami - Eye Research Center, Mashhad University of Medical Sciences
Elham Bakhtiari - Research Center for Patient Safety, Mashhad University of Medical Sciences, Mashhad, Iran
Mohsen Mohammadzade - Eye Research Center, Mashhad University of Medical Sciences
Seyed Hossein Ghavami Shahri - Assistant Professor of Ophthalmology Department of Ophthalmology, School of Medicine Khatam Al Anbiya Hospital Mashhad University of Medical Sciences
Mohammad Yaser Kiarudi - Eye Research Center, Mashhad University of Medical Sciences
Mahshid Sadeghi kakhki - emamat blv- ۱۷th emamat st- No۱۰۰- ۱th floor-Mashhad-Iran
Majid Abrishami - Eye Research Center, Farabi Eye Hospital; Tehran University of Medical Sciences, Tehran, Iran

Background: The prevalence of Retinopathy of Prematurity (ROP) is rising in Iran. We aimed to evaluate the clinical and demographic characteristics of ROP infants who need treatment, the type of treatment, and the complications in the years ۲۰۱۸ to ۲۰۲۲. Methods: This is a cross-sectional study. We evaluated the patient’s electronic medical records from ۲۰۱۸ to ۲۰۲۲. The required data was extracted from the registry dataset, including demographics, clinical characteristics of infants who required treatment, and the type and severity of treatment-related complications. Results: From ۱۰,۱۵۹ infants referred to the retinopathy of prematurity clinic from the beginning of ۲۰۱۸ to ۲۰۲۲, ۵۰۰۸ subjects (۴۹.۲۹%) were suffering from ROP, among whom ۴۱۶ (۸.۳%) patients needed treatment for ROP. The mean ± Standard Deviation (SD) of birth age and birth weight were ۲۸.۶۶ ± ۲.۲۴ weeks and ۱۲۲۷.۲۴ ± ۳۷۵.۹۷ grams. While most of our patients (۷۴۲ eyes, ۹۶.۴%) underwent Intravitreal Bevacizumab (IVB) injection as the treatment modality, laser photocoagulation was performed for ۲۵ eyes. Four eyes received pars plana vitrectomy treatment. The recurrent disease occurred in ۲۳ patients (۴۴ eyes). Birth age, birth weight, and the time of oxygen therapy were significantly different between the treatment responders and the neonates who experienced the recurrent disease. Conclusion: In this study, we showed that the birth age and weight of neonates who experienced a relapse were significantly lower. Besides, the results of treatment with IVB injection were satisfactory, with a relatively low recurrence rate and minimal complications.

Retinopathy of prematurity,,, ,،Treatment,,, ,،Intravitreal injection,,, ,،Anti-VEGF